Original Query: ALL
Previous Study | Return to List | Next Study

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00198133
Recruitment Status : Completed
First Posted : September 20, 2005
Results First Posted : January 25, 2016
Last Update Posted : January 25, 2016
Information provided by (Responsible Party):
Patrick Joseph Loehrer Sr., Indiana University School of Medicine

Brief Summary:
To study the efficacy of Alimta as a single agent in thymic cancers

Condition or disease Intervention/treatment Phase
Thymoma Thymic Carcinoma Drug: Premetrexed (Alimta) Phase 2

Detailed Description:
The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting efficacy of a single agent such as premetrexed a reasonable objective since these malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to antineoplastic agents.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
Study Start Date : January 2005
Primary Completion Date : December 2006
Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thymus Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Pemetrexed
Pemetrexed infusion once every 21 days (one cycle).
Drug: Premetrexed (Alimta)
Pemetrexed will be 500 mg/m2 IV every 3 weeks

Primary Outcome Measures :
  1. Objective Response Rate (Complete and Partial Response) [ Time Frame: Up to 3 years ]
    The percent of patients having an objective response (complete or partial response) will be estimated with a 95% exact binomial confidence interval for the percent of patients receiving drug. RECIST v1.0 will be used. At least a 30% decrease in the sum of the longest diameter of target lesions in reference to the baseline longest diameter will need to take place to be considered an objective response.

Secondary Outcome Measures :
  1. Duration of Remission [ Time Frame: Time from the date of remission until progression or death, assessed up to 3 years ]
    Will be examined using Kaplan-Meier estimates. Time from earliest confirmed remission criteria until death or progression will be calculated. If a patient continued to be in remission at the end of the study, they will be censored at their last evaluation in the analysis.

  2. Grade 3/4 Treatment Related Adverse Events [ Time Frame: Up to 3 years ]
    To determine the toxicity of premetrexed in this patient population, the number of patients who experienced grade 3 or 4 adverse events will be reported that were treatment related (possibly, probably, definitely).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery. Original biopsy of tumor is sufficient for diagnoses unless otherwise clinically indicated.
  • Patients must have measurable disease with at least one bidimensional measurable lesion. Any scans or x-rays used to document measurable disease must be obtained with 6 weeks prior to registration.
  • Patients may have had prior chemotherapy for metastatic disease
  • Adequate organ function as defined by: bili </=1.5; calc. crt clr of >/=45; hematologic-granulocytes >/=1500 & plt >/=100K.
  • Patients who are receiving a stable dose of corticosteroids for myasthenia gravis are eligible.
  • ECOG performance status of 0 or 1

Exclusion Criteria:

  • Acute intercurrent infection or complications
  • pregnancy or lactating patients
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents.
  • Presence of clinically relevant third-space fluid collections that cannot be controlled by a procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00198133

United States, Indiana
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Patrick Joseph Loehrer Sr.
Principal Investigator: Patrick Loehrer, M.D. Indiana University

Responsible Party: Patrick Joseph Loehrer Sr., Professor of Medicine, Indiana University School of Medicine Identifier: NCT00198133     History of Changes
Other Study ID Numbers: 0412-18; IUCRO-0088
First Posted: September 20, 2005    Key Record Dates
Results First Posted: January 25, 2016
Last Update Posted: January 25, 2016
Last Verified: December 2015

Keywords provided by Patrick Joseph Loehrer Sr., Indiana University School of Medicine:
Thymic Carcinoma

Additional relevant MeSH terms:
Thymus Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Complex and Mixed
Thoracic Neoplasms
Neoplasms by Site
Lymphatic Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors